Syndivia is participating in the World ADC San Diego 2017

Meet us at the 8th World ADC San Diego on September 20-22, 2017, and learn about exciting new conjugation technologies offered by Syndivia.

Syndivia wins the France Tech Transfer Invest Award

PARIS, France, February 2, 2017 -- Syndivia wins the France Tech Transfer Invest Award during a Tech Tour event that took place in Paris on 1-2 February 2017. The event is a collaboration between the SATT, Tech Tour, Bpifrance and its EuroQuity platform and aims to efficiently and effectively support French tech companies to meet and engage with international investors and corporate partners.
For more information on the event visit: http://techtour.com/events/view.aspx?events_pages_id=7749

OGD2 Pharma and Syndivia launch collaboration to develop an ADC targeting the O-acetyl-GD2 cancer antigen

NANTES, France, Sept. 6, 2016 (GLOBE NEWSWIRE) -- OGD2 Pharma SAS, a biotechnology company developing innovative anti-cancer therapies targeting the O-acetylated form of the GD2 ganglioside (OAcGD2), today announces a collaboration with Syndivia SAS, a biotechnology company that provides best-in-class bioconjugation technologies for the development of Antibody-Drug Conjugates (ADC).

Full press release available at: http://globenewswire.com/news-release/2016/09/06/869521/10164974/en/OGD2-Pharma-and-Syndivia-launch-collaboration-to-develop-an-ADC-targeting-the-O-acetyl-GD2-cancer-antigen.html

Syndivia receives the EU’s Horizon 2020 grant

The European Commission has named Syndivia as one of the new Phase 1 beneficiaries of the European Union's SME Instrument. SME Instrument is a highly competitive grant that supports close-to-market activities, with the aim to give a strong boost to breakthrough innovation. Highly innovative SMEs with a clear commercial ambition and a potential for high growth and internationalisation are the prime target. The SME Instrument Phase 1 grant is aimed to fund the feasibility assessment of Syndivia's next-generation targeted cancer therapies.

Meet us at the SMi's annual ADC Summit

May 23-24, Syndivia's CEO will be giving a talk at the SMi's annual ADC Summit in London.
The topics covered in the talk will include:
•    New ADC linkers with increased serum stability
•    Next-generation DM1- and MMAE-based payloads
•    Expanding the scope of ADC targets by fine-tuning the drug release properties
For more information, visit the website of the conference:
https://www.smi-online.co.uk/pharmaceuticals/uk/adc-summit